Nexavar India Nexavar Beijing Purchasing Agency-Nexavar India 13621079267

/ () Pay on delivery, make medicine with conscience, sell fake medicine and kill the whole family...
( / ()
( / ()
( / ( ) [Usage and Dosage] Recommended dosage The recommended dosage of Nexavar (sorafenib) is each time (.), twice a day, on an empty stomach or with a low-fat or medium-fat diet.
( / ( ) Instructions for administration: Take orally and swallow with a glass of warm water. The treatment time should be continued until the patient can no longer benefit clinically or an intolerable toxic reaction occurs. Dosage adjustment and special instructions for use. Treatment of suspected adverse reactions includes suspending or reducing Nexavar ( Sorafenib) dosage, if necessary, reduce the dosage of Nexavar (Sorafenib) to once a day or once every other day, each time. (.).
( / () Make corresponding adjustments based on skin toxicity Dosage Adjustment
(/() grade skin adverse reactions such as numbness, hypoesthesia, paresthesia, numbness, painless swelling, erythema of hands and feet or discomfort but does not affect daily activities occur at any time, it is recommended that the dose be adjusted to continue Use this product and give local treatment to eliminate symptoms.
Grade ( / () skin adverse reactions include painful erythema and swelling of the hands and feet, and/or discomfort in the hands and feet that affects daily life. When it first occurs, the dose is adjusted to Continue to use this product and give local treatment to eliminate symptoms. If symptoms do not improve within days or appear for the second or third time, interrupt treatment with this product until the toxicity is relieved to level 1. When restarting treatment with this product, reduce to Single dose (daily or every other day). When the fourth occurrence occurs, treatment with this product should be terminated.
( / () grade skin adverse reactions: desquamation, ulcers, blistering of hands and feet, pain or lead to Severe hand and foot discomfort in which the patient is unable to work and lead a normal life. When the first or second occurrence occurs, treatment with this product should be interrupted until the toxicity has resolved to grade 1. When treatment with this product is re-initiated, reduce to a single dose (daily. or the next day.). When it occurs for the third time, treatment with this product should be terminated.
( / () Pediatric patients There is no safety and efficacy data on the use of Nexavar (sorafenib) in pediatric patients. Geriatric (over 10 years) Gender and weight No dosage adjustment is required based on the patient's age (over 10 years), gender, or weight.
( / () Patients with hepatic impairment No dosage adjustment is required for patients with mild to moderate hepatic impairment ( and ) .Nexavar (sorafenib) has not been studied in patients with severe hepatic impairment.
( / () Renal Impairment Patients No dose adjustment is required in patients with mild to moderate renal impairment. Severe renal impairment has not been reported or sorafenib in patients undergoing dialysis.